Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials

Published:2021-06 Issue:3 Volume:161 Page:653-659
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Nitecki Roni,Melamed Alexander,Gockley Allison A.,Floyd Jessica,Krause Kate J.,Coleman Robert L.,Matulonis Ursula A.,Giordano Sharon H.,Lu Karen H.,Rauh-Hain J. Alejandro

Funder

National Cancer Institute

Merck

National Center for Advancing Translational Sciences

Janssen Pharmaceuticals

National Institutes of Health

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference50 articles.

1. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-Ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer;Kaye;J. Clin. Oncol.,2012

2. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial;Oza;Lancet. Oncol.,2015

3. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1/2 mutation (SOLO3): a randomized phase III trial;Penson;J. Clin. Oncol.,2020

4. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial;Ledermann;Lancet. Oncol.,2016

5. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer;Mirza;N. Engl. J. Med.,2016

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms;ESMO Open;2024-09

2. Risk assessment and genetic counseling for hematologic malignancies—Practice resource of the National Society of Genetic Counselors;Journal of Genetic Counseling;2024-08-27

3. Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants;Gynecologic Oncology;2024-08

4. Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer;International Journal of Molecular Sciences;2024-03-09

5. PARP Inhibitors in Prostate Cancer – Understanding the Current Landscape;International Journal of Cancer Care and Delivery;2024-01-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3